Drugs / LY2969822
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02018887 | Dec 2013 → Feb 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2969822 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02018887 ↗ |
| Action | Activate | “Metabotropic glutamate receptor 3 agonist” CHEMBL3545270 ↗1“Metabotropic glutamate receptor 2 agonist” CHEMBL3545270 ↗ |
| Route | Oral | “Capsules administered orally” NCT02018887 ↗ |
| Target | GRM2 | “Metabotropic glutamate receptor 2 agonist” CHEMBL3545270 ↗ |
| Target | GRM3 | “Metabotropic glutamate receptor 3 agonist” CHEMBL3545270 ↗ |